Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit H Mulsant

Showing results (471-480 of 607) with videos related to

Pageof 61
Sort By:
The American Journal of Psychiatry|January 11, 2017
Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older AdultsVictoria S Marshe, Malgorzata Maciukiewicz, Soham Rej, et al.
Journal of Affective Disorders|April 5, 2025
Prediction of remission of pharmacologically treated psychotic depression: A machine learning approachEmily Carter, Samprit Banerjee, George S Alexopoulos, et al.
The Pharmacogenomics Journal|November 23, 2024
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey studySamar S M Elsheikh, Victoria S Marshe, Xiaoyu Men, et al.
Journal of Affective Disorders|August 27, 2025
Sociodemographic and clinical characteristics among individuals with bipolar disorder in Pakistan - a gender-focused analysisSiqi Xue, Muqaddas Asif, Ameer B Khoso, et al.
Journal of Affective Disorders|November 19, 2021
Metabolic function in patients with bipolar depression receiving anti-inflammatory agents: Findings from the MINDCARE study, a multicentre, randomised controlled trialStefan Kloiber, Brett D M Jones, John Hodsoll, et al.
Schizophrenia Research|March 12, 2015
Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET studyShinichiro Nakajima, Fernando Caravaggio, David C Mamo, et al.
JAMA Psychiatry|February 27, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical TrialAristotle N Voineskos, Benoit H Mulsant, Erin W Dickie, et al.
The American Journal of Psychiatry|January 5, 2019
Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental IllnessColin Hawco, Robert W Buchanan, Navona Calarco, et al.
JAMA|August 21, 2019
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical TrialAlastair J Flint, Barnett S Meyers, Anthony J Rothschild, et al.
Journal of Clinical Psychopharmacology|April 28, 2026
Toward Precision Psychiatry: Using Clinical and Pharmacokinetic Data to Increase Antidepressant Dose or Change Treatment in Late-Life DepressionHelena K Kim, Xiaoyu Men, Samar S M Elsheikh, et al.
Pageof 61

Showing results (471-480 of 607) with videos related to

Sort By:
Pageof 61
The American Journal of Psychiatry|January 11, 2017
Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older AdultsVictoria S Marshe, Malgorzata Maciukiewicz, Soham Rej, et al.
Journal of Affective Disorders|April 5, 2025
Prediction of remission of pharmacologically treated psychotic depression: A machine learning approachEmily Carter, Samprit Banerjee, George S Alexopoulos, et al.
The Pharmacogenomics Journal|November 23, 2024
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey studySamar S M Elsheikh, Victoria S Marshe, Xiaoyu Men, et al.
Journal of Affective Disorders|August 27, 2025
Sociodemographic and clinical characteristics among individuals with bipolar disorder in Pakistan - a gender-focused analysisSiqi Xue, Muqaddas Asif, Ameer B Khoso, et al.
Journal of Affective Disorders|November 19, 2021
Metabolic function in patients with bipolar depression receiving anti-inflammatory agents: Findings from the MINDCARE study, a multicentre, randomised controlled trialStefan Kloiber, Brett D M Jones, John Hodsoll, et al.
Schizophrenia Research|March 12, 2015
Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET studyShinichiro Nakajima, Fernando Caravaggio, David C Mamo, et al.
JAMA Psychiatry|February 27, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical TrialAristotle N Voineskos, Benoit H Mulsant, Erin W Dickie, et al.
The American Journal of Psychiatry|January 5, 2019
Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental IllnessColin Hawco, Robert W Buchanan, Navona Calarco, et al.
JAMA|August 21, 2019
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical TrialAlastair J Flint, Barnett S Meyers, Anthony J Rothschild, et al.
Journal of Clinical Psychopharmacology|April 28, 2026
Toward Precision Psychiatry: Using Clinical and Pharmacokinetic Data to Increase Antidepressant Dose or Change Treatment in Late-Life DepressionHelena K Kim, Xiaoyu Men, Samar S M Elsheikh, et al.
Pageof 61